DE-LYCRA
26.7.2022 14:02:28 CEST | Business Wire | Press release
The LYCRA Company , a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and personal care industries, today announced a partnership with Browzwear that will provide designers using VStitcher and Lotta, the pioneering platforms for 3D fashion design, the ability to quickly and easily develop products incorporating fabrics containing LYCRA®, LYCRA® T400®, and COOLMAX® fibers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005001/en/
The partnership with Browzwear is the latest element of a multifaceted digital transformation that The LYCRA Company began last year with the launch of the LYCRA ONE™ customer portal, an online marketplace connecting brands, retailers, and garment makers to a global network of partner mills in a virtual capacity. The expansion of The LYCRA Company’s digital infrastructure is enabling new forms of engagement with its global customer base, and online platforms, like Browzwear, demonstrate the differentiation and sources of innovation that The LYCRA Company is helping bring to its customers across the apparel value chain.
With the true-to-life visualizations made possible with Browzwear's innovative software, the industry's leading 3D software for apparel design and development, designers can digitally create activewear, denim, swimwear, ready-to-wear, and intimate apparel fashions using fabrics showcased in the LYCRA® Brand Materials Library. The Browzwear platform enables designers to visualize how garments made with LYCRA® fiber offer a comfortable, lasting fit that will move with the wearer.
All the materials with digital versions in the LYCRA® Brand Materials Library can be sourced directly from one of 15 global mills initially featured on Browzwear. These materials have been tested and certified by The LYCRA Company, ensuring they contain the company’s authentic fibers that are designed to meet consumer needs for comfort, fit and ease of movement. In addition, The LYCRA Company will continue to work with Browzwear to add new resources to the materials library as they become available, further enhancing the digital design capabilities.
This partnership also advances The LYCRA Company’s sustainability commitment to offering a variety of fiber and fabric solutions that reduce or divert waste and keep materials in use longer. Creating digital garments via Browzwear streamlines the production process and reduces the need to manufacture samples, saving time and reducing waste for more efficient and sustainable operations.
“At The LYCRA Company, innovation is in our DNA, and we constantly look at new ways to create value for our mill customers, brands, and retail partners," said Julien Born, CEO of The LYCRA Company. "Digital transformation and sustainability offer opportunities, but also stretch our approach to innovation as fast and meaningful advances in those areas cannot be achieved alone. By teaming up with Browzwear, we are taking an important step in that direction, with the goal of ultimately changing the way the apparel industry will engage and interact digitally to optimize the sourcing of high-quality fabrics that extend garment wear life and reduce the need for samples.”
" We are thrilled to collaborate with The LYCRA Company and enable our users to leverage its well-known performance fibers to better incorporate them into designs, faster, easier, and more sustainably. Our Fabric Analyzer ensures the 3D versions of fabrics made with fibers from the LYCRA® Brand Materials Library result in true-to-life simulations of the garments, with physics and movement that reflect the durability and unique functionality of these fibers,” said Avihay Feld, Browzwear co-founder and CEO. “We believe this partnership will drive positive impact throughout the industry by helping brands and retailers to operate a more sustainable, efficient development process."
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA® , LYCRA HyFit® , LYCRA® T400® , COOLMAX® , THERMOLITE® , ELASPAN® , SUPPLEX® , and TACTEL® . The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
LYCRA® and COOLMAX® are trademarks of The LYCRA Company.
About Browzwear
Founded in 1999, Browzwear is a pioneer of 3D digital solutions for the fashion industry, driving seamless processes from concept to commerce. For designers, Browzwear accelerates collection development, opening limitless opportunities to create iterations of styles. For technical designers and pattern makers, Browzwear rapidly fits graded garments with accurate, true-motion material replication. For manufacturers, Browzwear’s Tech Pack delivers everything needed to produce physical garments perfectly the first time, and at every step from design to production. Worldwide, more than 650 organizations such as Columbia Sportswear, PVH Group and VF Corporation leverage Browzwear’s open platform to streamline processes, collaborate and pursue data-driven production strategies so they can sell more while manufacturing less, which increases both ecologic and economic sustainability. For more information, visit www.browzwear.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom